Form EFFECT AN2 Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 20, 2026 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AN2 Therapeutics gets FDA clearance for epetraborole PV trial
- ILC Dover Agrees to Pay Record High $13 Million to Settle Cybersecurity False Claims Act Case Brought by Whistleblower Law Collaborative Client
- Hypercholesterolemia Market Projected to Achieve Substantial Growth by 2036, Led by Key Companies and Strategic Developments | Novartis, Esperion Therapeutics, Esperion Therapeutics, EPIC BIO, Amytrx
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
